Cellebrite DI Ltd. CLBT
10.79
(0.58)
(5.10%)
as of 25 Sep
- Market cap
- $2.9B
- P/E
- 45.0×
Follow CLBT
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
60.83 | 47.52 | 56.34 | 59.77 |
+8 more quarters Free account |
P/S ratio |
7.03 | 6.84 | 9.16 | 9.90 | |
P/FCF ratio |
0.00 | 1,262.12 | 402.64 | 33.31 | |
P/Operating CF |
205.54 | 170.80 | 50.18 | 135.62 | |
P/B ratio |
6.72 | 6.65 | 9.00 | 10.08 | |
Price to Tangible BV |
12.19 | 12.91 | 15.38 | 11.03 | |
EV/Sales |
6.17 | 5.98 | 8.24 | 8.74 | |
EV/EBITDA |
41.53 | 38.75 | 51.59 | 57.79 | |
EV/Operating CF |
20.14 | 17.20 | 22.58 | 26.11 | |
EV/FCF |
(158.29) | 1,102.67 | 362.24 | 29.43 | |
Quick Ratio |
1.52 | 1.43 | 1.47 | 1.99 | |
Current Ratio |
1.62 | 1.54 | 1.56 | 2.11 | |
Net Debt/EBITDA |
(28.32) | (28.65) | (17.77) | (24.79) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.58 | 0.60 | 0.58 | 0.62 | |
Operating CF/Net income |
2.76 | 1.82 | 4.08 | 1.65 | |
Capex/Depreciation |
(1.34) | (1.72) | (40.02) | (1.50) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
27.42% | 27.96% | 23.18% | 22.32% | |
Selling, General and Administrative Expense of Revenue |
48.06% | 47.46% | 45.38% | 46.50% | |
Intangible Assets out of Total Assets |
0.24 | 0.26 | 0.21 | 0.05 | |
Share Based Compensation of Revenue |
11.63% | 11.21% | 9.31% | 12.15% | |
Graham Net Nets |
0.04 | 0.03 | 0.03 | 0.06 | |
Graham Number |
3.43 | 3.68 | 3.80 | 3.58 | |
Earnings Yield |
1.64% | 2.10% | 1.77% | 1.67% | |
Free Cash Flow Yield |
(0.55%) | 0.08% | 0.25% | 3.00% | |
Revenue per Share |
0.53 | 0.52 | 0.53 | 0.52 | |
Operating CF per Share |
0.07 | 0.08 | 0.36 | 0.14 | |
Capex per Share |
(0.05) | (0.04) | (0.63) | (0.01) | |
Free Cash Flow per Share |
0.02 | 0.04 | (0.27) | 0.12 | |
Cash per Share |
1.79 | 1.74 | 1.81 | 2.16 | |
Shareholders Equity per Share |
2.17 | 2.07 | 2.00 | 1.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.17 | 2.07 | 2.00 | 1.84 | |
Free Cash Flow |
5.96 | 9.79 | (64.60) | 29.95 | |
Working Capital |
225.47 | 190.66 | 206.19 | 351.49 | |
Capital Expenditures |
(11.63) | (10.10) | (151.41) | (3.32) | |
Net Current Asset Value |
133.47 | 99.12 | 121.32 | 281.77 | |
EV/EBIT |
56.79 | 46.85 | 58.96 | 64.92 | |
Capex to Sales |
0.09 | 0.08 | 1.18 | 0.03 | |
Net Profit Margin |
4.86% | 8.53% | 16.50% | 16.02% | |
Price to Operating Income |
64.72 | 53.63 | 65.53 | 73.49 | |
| Other line items | |||||
Average Receivables |
101.95 | 76.94 | 93.67 | 98.96 | |
Average Payables |
86.84 | 77.33 | 81.24 | 67.69 | |
Average Inventory |
8.96 | 8.25 | 8.27 | 9.19 | |
Average Assets |
890.87 | 831.09 | 814.71 | 731.78 | |
Average Common Equity |
473.26 | 437.02 | 410.17 | 373.00 |
Columns are period end dates